China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s Category 2 drug QP001 in mainland China via a licensing deal. QP001, a nonsteroidal anti-inflammatory drug (NSAID), is a me-better version of Boehringer Ingelheim’s Mobic (meloxicam) and is awaiting regulatory decisions in China and the United States.
Mechanism and Benefits of QP001
QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces or blocks the synthesis of prostaglandins (PGs) in the affected area by inhibiting the upregulation of COX-2 activity in inflammation and pain sites. This mechanism allows QP001 to exert anti-inflammatory and analgesic effects while having a relatively small impact on cyclooxygenase-1 (COX-1), which is crucial for maintaining normal physiological functions in various tissues of the human body. QP001 is the first daily long-acting analgesic NSAID injection in China that can achieve sustained and effective pain relief for 24 hours with a single injection.
Clinical Studies and Market Potential
Two Phase III clinical studies have demonstrated that QP001 can significantly reduce morphine use and pain scores in subjects after orthopedic and abdominal surgery. These results suggest that QP001 has the potential to become a major product in the pain relief field, following in the footsteps of flurbiprofen, and could significantly impact the management of postoperative pain in China.-Fineline Info & Tech
Leave a Reply